Olmesartan Medoxomil/Amlodipină Accord (Olmesartan Medoxomil, Amlodipine)

• Olmesartan/Amlodipine is indicated for the management of hypertension, a condition characterized by chronically elevated arterial pressure.
• Hypertension: reduces systolic and diastolic blood pressure and lowers cardiovascular risk.
• Essential hypertension: provides effective blood‑pressure control when monotherapy is insufficient.
• High blood pressure: improves long‑term outcomes by maintaining target blood‑pressure levels.

• Olmesartan Medoxomil selectively blocks angiotensin II type 1 (AT1) receptors, preventing angiotensin‑II‑mediated vasoconstriction and aldosterone release. Amlodipine inhibits L‑type calcium channels in vascular smooth‑muscle cells, causing arterial dilation. By combining an angiotensin‑II receptor blocker with a calcium‑channel blocker, the formulation produces additive vasodilatory effects, reduces peripheral resistance, and achieves more consistent blood‑pressure lowering than either component alone.

The combination may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Dizziness
• Headache
• Peripheral edema
• Flushing
• Fatigue
• Palpitations

Serious or Rare Side Effects

• Angioedema
• Severe hypotension
• Myocardial infarction
• Hepatic dysfunction
• Severe allergic reactions (e.g., Stevens‑Johnson syndrome)
• Rhabdomyolysis

When prescribing Olmesartan/Amlodipine, clinicians should observe several safety considerations.

• Blood pressure monitoring: check regularly to avoid excessive hypotension.
• Renal or hepatic impairment: dose may need adjustment and patients require close observation.
• Pregnancy: contraindicated in pregnancy (Category D) due to risk of fetal toxicity.
• Lactation: avoid use while breastfeeding because drug may be excreted in milk.
• Elderly patients: start at lower dose and monitor for orthostatic effects.
• Store at below 25°C: keep in original packaging, protect from moisture and light.

Olmesartan/Amlodipine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Concomitant use with aliskiren in diabetic patients: may increase risk of renal impairment and hyperkalemia.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise amlodipine plasma levels, leading to hypotension.
• Other antihypertensives (e.g., ACE inhibitors, beta‑blockers) used together: may cause additive blood‑pressure lowering.
• Lithium therapy: olmesartan may increase lithium concentrations, risking toxicity.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce amlodipine exposure, decreasing efficacy.
• Diuretics: can enhance antihypertensive response, requiring blood‑pressure checks.
• Beta‑blockers: combined use may increase risk of bradycardia.
• ACE inhibitors or ARBs: monitor potassium levels for hyperkalemia.
• Grapefruit juice: may modestly increase amlodipine concentrations.